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OBJECTIVES: China’s health care expenditure is one of the largest in the world and
is set to grow strongly in the foreseeable future. A greater understanding of the
impact of economic and policy factors on China’s health care expenditure and its
growth trend will help major pharmaceutical firms make strategic plans in the
emerging markets.METHODS: Dynamic least squares regression was used on an-
nual time series data (1970 to 2011). The dependent variable was real per capita
health care expenditure (RPCHE). The explanatory variables included real per cap-
ita GDP (RPCGDP), relative price for consumer health spending (RPCMED) and
lagged variables. The analysis used data fromWHO, China Statistical Yearbook and
IHS Healthcare Forecasting. The main independent variables were RPCGDP and
RPCMED. RESULTS: A negative correlation was found between estimated RPCHE
and RPCMED; and a positive correlation between estimated RPCHE and RPCGDP.
The main results can be summarized as follows: 1) For every 1% rise in the growth
rate of RPCMED, there is a 1.16% decrease in the level of RPCHE, and 2) the income
elasticity of real health care expenditure is 15%. Based on the estimations, forecasts
on total health care expenditureweremade for the forecast period (2012-2020). The
main independent variables—RPCMEDandRPCGDP—were derived from IHSMacro
for the forecast period. To capture health care policy’s impact on health care ex-
penditure, add factors were used in the forecast. According to the forecast, China’s
total health care expenditure is projected to grow 15.8% this year and 14.8% next.
CONCLUSIONS: In terms of economic impact, relative price for consumer health
spending and income play a major role in determining health care expenditure. In
terms of policy impact, China’s health care reform—via massive health insurance
expansion—will be a key driver of health care expenditure growth throughout the
forecast horizon, although there are increasing pressures on pricing and significant
regional disparities.
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HEALTH FINANCING FOR PRISONERS WITH HIV: LESSON LEARNED FROM
INDONESIA
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OBJECTIVES:To obtain information on spending onprevention and care-treatment
programs among prisoners in two prisons: Jakarta and Bali and who finance the
program. METHODS: Retrospective data was collected from two prisons: Bali and
Jakarta. Cost was estimated from government and partners perspective. Both
quantitative and qualitative analysis were done. A modified activity-based costing
was done supported with document review and interviews. RESULTS: HIV inter-
vention in Indonesia has been improving with support from the Government and
international partners. At the moment several prisons in Java are chosen as model
for HIV-AIDS programs for prisoners, including VCT, Lab-test, ART, OI treatment
and hospital care. Total spending in Bali was USD 26.239 per-year and unit cost was
USD 78, while in Jakarta unit cost was USD 426. These spending even higher if other
activities such as substitution and treatment at hospital were included. Some pro-
grams such as Methadone theraphy, condom and ART were conducted in collabo-
ration with District Health Office and local hospital, and funded by government.
Interestingly, program for prisoners in Bali includes spiritual theraphy such as yoga
and dancing, initiated using funds from international partners. High cost for CD4
and ART were covered by central government, while operational cost was sup-
ported by local government. Networking with other institution become critical,
since no direct costs actually covered by the prisons themselves. CONCLUSIONS:
Most of program intervention for prisoners supported by external partners. Sus-
tainability issue remain unclear since donor fundingwill be finished soon andmust
be replaced by government. Local government is expected to support continuity of
the program, but regions with low fiscal capacity are not able to ensure program
continuity.
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OBJECTIVES: Each year over a million patients in Australia delay seeing a General
Practioner (GP), and a similar number do not fill their prescriptions, because of the
cost. This failure to access necessary medications has economic and morbidity
implications in the long-term. In addition, reduced uptake affects company reve-
nue. Currently theUS Food andDrugAdministration (FDA) is considering a range of
measures to improve access to medicines, including making more drugs used for
common, under-treated conditions, available over-the-counter (OTC). This study
aimed to compare the costs to the patient and potential manufacturer price for a
sample of medicines that are available both OTC and on prescription in Australia.
METHODS: Costs of accessing diclofenac (25mg tablets) and omeprazole (20mg
tablets) via a GP prescription were compared to those for OTC. For medicines ob-
tained on prescription, patient co-payments were sourced from the Pharmaceuti-
cal Benefits Schedule (PBS) website, and the average cost of a GP visit. Costs of OTC
formulations were estimated based on a sample of pharmacies. The resultant cost
to patient and potential price to the manufacturer were calculated and compared.
RESULTS: For patients in Australia, OTC acquisition of medicines was up to 50%
less expensive per tablet than accessing treatment via GP prescription. The per-
tablet savings for patient were greater for omeprazole than for diclofenac. At the
point of sale, the cost per tablet of OTC products was 150%-500% of the ex-manu-
facturer cost for the PBS listed product. Therefore, an OTC strategy also appears to
be a commercially viable for manufacturers, even allowing for a pharmacy
mark-up. CONCLUSIONS: Down-scheduling from prescription-only to OTC may
decrease the direct costs of treatment for patients, while simultaneously increas-
ing the price per tablet to manufacturers: a win-win situation.
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OBJECTIVES: Replacement of Peripheral Venous Catheter (PVC) is sometimes re-
quired prematurely due to extravasation, catheter damage, complications such as
phlebitis. We evaluated the clinical and economic benefits of an integrated closed
intravenous catheter system (CICS) with pre-attached stabilization platform and
extension tube (Catheter A) which may reduce the occurrence of unscheduled
catheter replacement. METHODS: A prospective, open, quasi-random, and con-
trolled study was conducted to compare Catheter A and a conventional PVC (Cath-
eter B) in a 286-bed general hospital in Japan. Patients requiring PVCs for 72 hours
or more were enrolled and assigned to either Catheter A Group (Group A) or Cath-
eter B Group (Group B). Both catheters were secured with the same procedure and
regularly observed until removal. The Kaplan-Meier estimate for the replacement
rates for both catheters for 72 hours was calculated, and the cost difference be-
tween the groups was obtained using product prices and average nursing fees
published by the government. RESULTS: There were 358 patients evaluated: 193 in
Group A and 165 in Group B. One hundred forty three patients in Group A and 109
patients in Group B required catheter replacement because of extravasation, cath-
eter damage, complications, or scheduled catheter removal. The remaining 106
patients from both groups had catheters removed for unexpected reasons such as
earlier end of therapy and self-withdrawal. Excluding those 106 patients, therewas
a significant difference in the catheter survival curves between Group A and B
(p0.01, log-rank test). The total cost of catheter replacement for 72-hour use was
393 yen for Group A and 704 yen for Group B. CONCLUSIONS: The cost difference
between two catheters can be offset by savings generated from a lower event rate.
Along with total cost benefits, the use of CICS is considered to provide improved
safety to patients through decreased complications.
PHP51
MANAGEMENTS OF FEBRILE NEUTROPENIA AMONG NON-HODGKIN’S
LYMPHOMA PATIENTS IN TAIWAN
Lin WT1, Hsiao FY1, Chiang SC2, Wen YW3
1National Taiwan University, Taipei,Taiwan, 2Koo Foundation Sun Yat-Sen Cancer Center,
Taipei,Taiwan, 3Chang Gung University, Taoyuan,Taiwan
OBJECTIVES: Febrile neutropenia (FN) is a major complication in cancer patients
treated with chemotherapy, leading to infection-associatedmorbidity andmortal-
ity. Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is
recommended by recent clinical guidelines tomanage those patientswith high risk
of FN. Uncertainty in selecting patients who need G-CSF prophylaxis, however,
remains in clinical settings. The objectives of this study were to document the
utilization pattern of G-CSF and to analyze the potential risk factors of FN in non-
Hodgkin’s lymphoma (NHL) patients.METHODS: Eligible patients were those who
were older than 18 years, diagnosed with NHL, and initiated a new chemotherapy
regimen in 2010 at amedical center in Taiwan. All chemotherapy cycles received by
our study subjects were divided into two groups based on the occurrence of FN
during each cycle. All patients were followed until all the planned chemotherapy
courses were completed or one year after the first date of chemotherapy regimen.
Differences in patient characteristics between the FN and non-FN group were as-
sessed with chi-square tests for categorical variables and t-tests for continuous
variables. RESULTS: Two hundred and eighty-six courses for G-CSF prophylaxis
were evaluated in 72 patients receiving a total of 432 cycles of chemotherapy reg-
imen. Of these, 38 % of G-CSF was prescribed as primary prophylaxis, and 62 % as
secondary prophylaxis, with an average duration of 3 days. Differences between FN
and non-FN group which is statistically significance were history of chronic renal
failure or anemia (p0.0038, p0.0001), prophylactic use of G-CSF (p0.0192), per-
formance status (p0.0001), numbers of previous neutropenia (p0.0008), baseline
albumin or hemoglobin level (p0.0085, p0.0001). CONCLUSIONS: At this cancer
center in Taiwan, the duration of G-CSF administration is shorter than the recom-
mended. Differences between the two groups may be the possible risk factors, and
need to be further analyzed.
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OBJECTIVES: To compare pharmaceutical company and medical representatives
as drug information source with other conventional and advanced sources being
used by Doctors. METHODS: A total 103 doctors were interviewed personally by
using a structured validated questionnaire developed. Ransom and purposeful
samplingwas used to select the required sample. The data collectedwas evaluated
and represented in the form of total numbers and percentages. RESULTS: Among
103 doctors (52.42% or 54) mentioned that pharmaceutical companies andmedical
representatives are less useful source of information. 58.25% doctors responded
that Pharmaceutical company sponsored Education program as useful. A total of
17.47%mentioned it as very useful source of information for new drugs and 24.27%
doctors mentioned it as less useful. A total of 59.12% doctors mentioned medical
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journals and articles as very useful source of information and 35.92% doctorsmen-
tioned as useful source of information. Only 4.85% doctors believe this is less useful
source of drug information. 49.51% of doctors believe as very useful source of
information and 45.63% as useful. Only 4.85% doctorsmentioned that as less useful
source. Subscription based source showed that 41.74% doctors mentioned that as
very useful source and 49.51% mentioned that as useful source. A total of 8.73%
doctors mentioned that as less useful source. Informal discussions with other doc-
tors as drug information source is very useful for 47.57% doctors and useful for
46.60% while only 5.82% doctors mentioned that as less useful source of
information. CONCLUSIONS:Medical representative is not the option for success-
ful promotion, companies should also focus on other sources ex. medical journals,
internet sources which are highly appreciated among health care practitioners.
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OBJECTIVES:To accurately reflect actual price level of chemical drugs and changes,
this study deeply explored influencing factors of chemical drug price, constructed
chemical drug price index system and meanwhile sought methods to establish
price index of a specific type of chemical drugs.METHODS: Combination of quali-
tative and quantitative methods was used to explore establishment of chemical
drug price index. Expert evaluation and field survey were used to determine clas-
sification of chemical drugs, representatives and representatives’ weights. Ques-
tionnaire was used to determine key data in selection of chemical drug represen-
tatives. Field survey was used for data collection. RESULTS: On the basis of
chemical drug classification, representatives were determined step by step. By
collecting chemical drug price data in representative regions and manufacturers,
quantitative calculation of weight was performed. Selection route of quality ad-
justmentmethod and key quality collectionmethod when representative changed
in price index were investigated. Data collection protocol required to establish
chemical drug price index was proposed. Feasibility to establish chemical drug
price index system was explored and several main price indexes were proposed.
CONCLUSIONS: First, this study proposed specific methods to establish chemical
drug prices and solved the problem of selecting representative from various chem-
ical drugs. Second, quality adjustment decision process was proposed and key
quality adjustment methods were explored. Finally, as it is difficult for a single
overall chemical drug price index to completely reflect the general viewof chemical
drug price level and changes in our country, this study proposed an index system
including overall index, essential drug index and antibiotic index based on the
need of reality.
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OBJECTIVES:To provide information on the perceptions towards health promotion
activities among an urban poor population of Malaysia.METHODS: The study was
designed as a questionnaire based cross-sectional analysis. General public from
the district of Jelutong which is located in the state of Penang, Malaysia was con-
veniently approached for the study. The questionnaire asks about perceptions and
awareness towards health promotion activities. Descriptive statistics were used to
ascertain demographic characteristics of the study participants. Inferential statis-
ticswere employed tomeasure the extent of association among study variables. All
analysis was performed by SPPS v.16.0. RESULTS: Out of 480 respondents, a re-
sponse rate of 82.7%was achieved as 397 responded to the survey. The study cohort
was dominated by females (63.0%). Majority of the participants belonged to Malay
ethnicity (88.1%). One hundred and seventy two (43.3%) never attended a health
promotional campaign andmentioned lack of time and transport as potential bar-
riers. Among those who attended such activities, one third was satisfied with the
benefits of health campaigns and indicated an improvement in their quality of life.
Approximately 90% of the participants demanded accessible locations, common
language as mode of communication and complete medical checkup with profes-
sional advice at health promotional campaigns. CONCLUSIONS: Almost half of the
study population never attended a health promotional campaign. General public
should be educated and encouraged to participate in the health promotion activi-
ties. In addition, potential barrieers like lack of time and transport should be
avoided by organizing such events with the reach of the community members.
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OBJECTIVES:To assess the influence and role of antineoplastic and immunomodu-
lating agents in works and recommendations of AOTM. The main role of AOTM,
established in 2005, is to assess, appraise and prepare recommendations on financ-
ing all medical technologies and services claiming public money founding. Full
pharmacoeconomic evaluations of new therapies are required for all reimburse-
ment decisions. Manufacturers of antineoplastic and immunomodulating drugs
are obligated to provide HTA reports in order to have their drug reimbursed. Rec-
ommendations issued by AOTM have been based on Manufacturer‘s submission,
additional published data, experts and Polish public payer opinions.METHODS:All
recommendations issued by the AOTM until the end of 2011 were reviewed and
analyzed from the official website of AOTM. The recommendations related to an-
tineoplastic and immunomodulating drugs were distinguished. RESULTS: Among
400 AOTM recommendations analyzed, the largest number, 142 of 400 (36%) was
connected with antineoplastic and immunomodulating agents. 105 (74%) of them
regarding oncology treatment. Recommendation for non–drug technologies were
issued to 47 (12%) of 400 technologies. 58 (15%) applied to drugs used in the treat-
ment of nervous disorders, 34 (9%) metabolic disorders, 31 (8%) were related to
cardiovascular drugs, 21 (5%) genito-urinary system. 15% of verified documenta-
tions applied to other, single indications. CONCLUSIONS: The number of recom-
mendations issued for antineoplastic and immunomodulating drugs in compari-
son to other medicines reflects the importance and significance of this area of
medicine. Documents prepared by AOTM related to antineoplastic (cancer chemo-
therapy) treatment represent standards and trends in contemporary medicine.
PHP57
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OBJECTIVES: To evaluate clinical pharmacist interventions in geriatric outpatients
in terms of reduce the potentially deleterious consequences of polypharmacy.
METHODS: This intervention study was conducted by geriatric team from March
2011 until Aug 2011 in a medical center in Taiwan. Medication assessment was
undertaken in elderly outpatients aged 65 years or older who prescribed five or
more drugs concomitantly on the date of inclusion. We provided Comprehensive
Geriatric Assessment (CGA) to the patients. This process involves a comprehensive
medication history interview by pharmacist, structured therapy assessment, and
open communication between members of the medical team. RESULTS: A total of
51 patients were included during the period. The mean age was 79.4 ( 13.4) years;
53% were women. The patients took an average of 11 different long term medica-
tions. Medication reduction during 3 consequence pharmacist consulting in clinic
visit were 37.7%, 38.8%, 44.2% respectively. Finally, the mean number of medica-
tions prescribed per patient was 7.8. CONCLUSIONS: Pharmacists involved in CGA
has proved effective in reducing the number of prescriptions and daily drug doses
for patients by facilitating discontinuation of unnecessary or inappropriate medi-
cations.
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OBJECTIVES: To determine the direct medical cost of treatment in hospitalized
patients with adverse drug reactions (ADRs) in regional hospital in the provider’s
perspective. METHODS: The direct medical cost were collected from historical
profile of the inpatients who were identified using a list of ICD-10 and admitted in
special ward 4/2 in the fiscal year 2009 (From 11/7/2008 - 9/30/2009) in Nakhon
Prathom Hospital. They were divided into 2 groups 1) the patients admitted with
ADRs, and 2) the patients who admitted and developed ADRs after admission so
that extened hospitalization. The direct medical cost including cost of medical
care, cost of hospitalization and cost of laboratory. RESULTS: During study period
34(19.32%) cases of hospitalization patients admitted because of ADRs and
142(80.68%) caseswere verified to haveADRs after admission and 137(77.84%) cases
were excluded because they developed ADRs but not extended their hospitaliza-
tion.More than 35%of the patients age between 30 -44 years old in both groups. The
22(56.41%) patients in group 1 did not previously have ADR. Using Naranjo’s Algo-
rithm found thatmore than 60% of the patients were categorized in probable class.
ADR occurred in both groups more than 40% cause by antibiotics. Most frequent
ADR were maculopapular(30.77%) and urticaria(15.38%) as well as occurring more
than 1 symptoms(15.38%). Total direct medical cost in fiscal year 2010 from pa-
tients in both groupswas estimated at 185,935.75 Thai Baht, average directmedical
cost 4,767.58 Thai Baht per patient. The average direct medical cost in group 1 and
group 2 was 5,074.94 Thai Baht and 2,677.55 Thai Baht per person respectively.
CONCLUSIONS: This study emphasizedmedical and economic impact of the ADRs
treatments. ADR surveillance and pharmaceutical care activities would be com-
pared the cost and benefit.
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OBJECTIVES: Concerning insufficient collected data about pharmacists’ job satis-
faction in the Middle East and also in Iran, this countrywide study was conducted
to determine Iranian pharmacists’ job satisfaction in some job characteristics; ad-
ditionally, some causes of dissatisfaction among pharmacists have been
diagnosed.METHODS:A job satisfaction questionnairewas developed and reliabil-
ity tests were done by some experts in field of pharmacy practice. Then a sample
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